In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

Antimicrob Agents Chemother. 2012 May;56(5):2739-42. doi: 10.1128/AAC.00036-12. Epub 2012 Feb 21.

Abstract

Gonorrhea may become untreatable, and new treatment options are essential. We investigated the in vitro activity of the first fluoroketolide, solithromycin. Clinical Neisseria gonorrhoeae isolates and reference strains (n = 246), including the two extensively drug-resistant strains H041 and F89 and additional isolates with clinical cephalosporin resistance and multidrug resistance, were examined. The activity of solithromycin was mainly superior to that of other antimicrobials (n = 10) currently or previously recommended for gonorrhea treatment. Solithromycin might be an effective treatment option for gonorrhea.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Cephalosporin Resistance
  • Cephalosporins / pharmacology
  • Culture Media
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Erythromycin / pharmacology
  • Humans
  • Macrolides / chemistry
  • Macrolides / pharmacology*
  • Microbial Sensitivity Tests
  • Molecular Structure
  • Neisseria gonorrhoeae / drug effects*
  • Neisseria gonorrhoeae / growth & development
  • Neisseria gonorrhoeae / isolation & purification
  • Triazoles / chemistry
  • Triazoles / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Culture Media
  • Macrolides
  • Triazoles
  • Erythromycin
  • solithromycin